These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9368496)

  • 1. Neuroendocrine and behavioral effects of antisense oligonucleotides.
    Landgraf R; Naruo T; Vecsernyes M; Neumann I
    Eur J Endocrinol; 1997 Oct; 137(4):326-35. PubMed ID: 9368496
    [No Abstract]   [Full Text] [Related]  

  • 2. Antisense oligodeoxynucleotides as specific tools for studying neuroendocrine and behavioral functions: some prospects and problems.
    Nicot A; Pfaff DW
    J Neurosci Methods; 1997 Jan; 71(1):45-53. PubMed ID: 9125374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotides in the study of neuroendocrine systems.
    Morris M; Lucion AB
    J Neuroendocrinol; 1995 Jul; 7(7):493-500. PubMed ID: 7496391
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of NMDA-R1 antisense oligodeoxynucleotide administration: behavioral and radioligand binding studies.
    Zapata A; Capdevila JL; Tarrason G; Adan J; Martínez JM; Piulats J; Trullas R
    Brain Res; 1997 Jan; 745(1-2):114-20. PubMed ID: 9037399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anxiogenic-like effect of corticotropin-releasing factor receptor 2 antisense oligonucleotides infused into rat brain.
    Isogawa K; Akiyoshi J; Tsutsumi T; Kodama K; Horinouti Y; Nagayama H
    J Psychopharmacol; 2003 Dec; 17(4):409-13. PubMed ID: 14870953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotide-induced reduction in 5-hydroxytryptamine7 receptors in the rat hypothalamus without alteration in exploratory behaviour or neuroendocrine function.
    Clemett DA; Cockett MI; Marsden CA; Fone KC
    J Neurochem; 1998 Sep; 71(3):1271-9. PubMed ID: 9721753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates.
    Zhang M; Creese I
    Neurosci Lett; 1993 Oct; 161(2):223-6. PubMed ID: 7903803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of opioid tolerance by antisense oligodeoxynucleotides targeting neurogranin.
    Tang L; Shukla PK; Wang ZJ
    Eur J Pharmacol; 2006 Aug; 542(1-3):106-7. PubMed ID: 16797003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxytocin pathways mediate the cardiovascular and behavioral responses to substance P in the rat brain.
    Maier T; Dai WJ; Csikós T; Jirikowski GF; Unger T; Culman J
    Hypertension; 1998 Jan; 31(1 Pt 2):480-6. PubMed ID: 9453349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotides in psychopharmacology and behaviour: promises and pitfalls.
    Robinson ES; Nutt DJ; Jackson HC; Hudson AL
    J Psychopharmacol; 1997; 11(3):259-69. PubMed ID: 9305419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracerebroventricular administration of AT1 receptor antisense oligonucleotides inhibits the behavioral actions of angiotensin II.
    Sakai RR; He PF; Yang XD; Ma LY; Guo YF; Reilly JJ; Moga CN; Fluharty SJ
    J Neurochem; 1994 May; 62(5):2053-6. PubMed ID: 8158154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of altered 5-ht6 expression in the rat: functional studies using antisense oligonucleotides.
    Sleight AJ; Monsma FJ; Borroni E; Austin RH; Bourson A
    Behav Brain Res; 1996; 73(1-2):245-8. PubMed ID: 8788511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral changes following antisense oligonucleotide-induced reduction of organic cation transporter-3 in mice.
    Kitaichi K; Fukuda M; Nakayama H; Aoyama N; Ito Y; Fujimoto Y; Takagi K; Takagi K; Hasegawa T
    Neurosci Lett; 2005 Jul 1-8; 382(1-2):195-200. PubMed ID: 15911148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of calmodulin antisense oligonucleotides on chemoresponse in Paramecium.
    Yano J; Fraga D; Hinrichsen R; Van Houten JL
    Chem Senses; 1996 Feb; 21(1):55-8. PubMed ID: 8646492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medial prefrontal cortical injections of c-fos antisense oligonucleotides transiently lower c-Fos protein and mimic amphetamine withdrawal behaviours.
    Persico AM; Schindler CW; Davis SC; Ambrosio E; Uhl GR
    Neuroscience; 1998 Feb; 82(4):1115-29. PubMed ID: 9466435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides.
    Juliano RL; Alahari S; Yoo H; Kole R; Cho M
    Pharm Res; 1999 Apr; 16(4):494-502. PubMed ID: 10227702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A decrease in angiotensin receptor binding in rat brain nuclei by antisense oligonucleotides to the angiotensin AT1 receptor.
    Ambühl P; Gyurko R; Phillips MI
    Regul Pept; 1995 Oct; 59(2):171-82. PubMed ID: 8584752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense inhibition of the brain kallikrein-kinin system.
    Madeddu P; Parpaglia PP; Glorioso N; Chao L; Chao J
    Hypertension; 1996 Dec; 28(6):980-7. PubMed ID: 8952586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracerebroventricular administration of angiotensin type 1 (AT1) receptor antisense oligonucleotides attenuate thirst in the rat.
    Sakai RR; Ma LY; He PF; Fluharty SJ
    Regul Pept; 1995 Oct; 59(2):183-92. PubMed ID: 8584753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotides fail to inhibit the expression of central beta adrenergic receptors.
    Zhang K; O'Donnell JM
    Res Commun Mol Pathol Pharmacol; 1997 Jan; 95(1):21-32. PubMed ID: 9055346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.